Solventum (NYSE:SOLV – Get Free Report) issued its quarterly earnings data on Thursday. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.31 by $0.10, Zacks reports. Solventum updated its FY 2025 guidance to 5.450-5.650 EPS.
Solventum Price Performance
Solventum stock traded down $0.58 during mid-day trading on Thursday, reaching $83.46. 1,499,791 shares of the stock traded hands, compared to its average volume of 1,000,305. The business’s 50-day moving average is $71.92 and its 200-day moving average is $69.63. Solventum has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.
Wall Street Analyst Weigh In
SOLV has been the subject of several research reports. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Mizuho began coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. Finally, Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $71.86.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Industrial Products Stocks Investing
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- What Are Dividend Contenders? Investing in Dividend Contenders
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.